apraglutide
Peptide
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
Latest reported trial: STARS (NCT04627025) · Phase 3 · met primary endpoint · grade pending
Company guidance: data expected in 2029 (NCT04627025; Ironwood Pharmaceuticals, 5 Nov 2026). “Subject to the results of the STARS-2 clinical trial, Ironwood plans to file for regulatory approval in 2029 and aims to identify” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
STARS NCT04627025 · Short Bowel Syndrome Registry: NCT04627025 | 3 | Relative change from baseline in actual weekly PS volume at Week 24. (At week 24 of treatment) 2024-01-02 | Relative change in weekly parenteral support volume at week 24: -25.5% apraglutide vs -12.5% placebo, P=.001. | not yet graded | link ↗ |
View 1 more trial
NCT07742735 NCT07742735 · Short Bowel Syndrome Registry: NCT07742735 | 3 | Relative change from baseline in actual weekly PS volume at Week 24. 2028-10 | In progress: results expected 1 Oct 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other GLP-2 receptor drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Short Bowel Syndrome: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Apraglutide: this drug | Phase 3 | Peptide | GLP-2 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Teduglutide (Gattex) | Approved | Peptide | GLP-2 receptor | Partial signal | NCT02682381: Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 (Baseline through Week 24): 0.025 mg/kg/Day Teduglutide — Participant Diary: 13 Participants; Investigator Prescribed: 13 Participants | 0.05 mg/kg/Day Teduglutide — Participant Diary: 18 Participants; Investigator Prescribed: 18 Participants | Standard of Care — Participant Diary: 1 Participants; Investigator Prescribed: 2 Participants NCT00798967: Responder (Weeks 20 and 24): Teduglutide 27 subjects | Placebo 13 subjects | |
| Crofelemer (Mytesi) | Phase 2 | Small molecule | Chloride channel (intestinal epithelium) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow apraglutide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.